Clearpoint Neuro Inc
$ 11.79
12.29%
17 Apr - close price
- Market Cap 353,535,000 USD
- Current Price $ 11.79
- High / Low $ 11.82 / 10.60
- Stock P/E N/A
- Book Value 0.95
- EPS -0.90
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.96 %
- 52 Week High 30.10
- 52 Week Low 8.27
About
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-12 | 2025-05-05 | 2025-02-26 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-03-12 | 2023-11-09 | 2023-08-08 | 2023-05-11 |
| Reported EPS | -0.27 | -0.21 | -0.21 | -0.22 | -0.2 | -0.18 | -0.16 | -0.16 | -0.19 | -0.2 | -0.29 | -0.23 |
| Estimated EPS | -0.185 | -0.18 | -0.2 | -0.16 | -0.1737 | -0.17 | -0.2 | -0.19 | -0.2 | -0.25 | -0.19 | -0.18 |
| Surprise | -0.085 | -0.03 | -0.01 | -0.06 | -0.0263 | -0.01 | 0.04 | 0.03 | 0.01 | 0.05 | -0.1 | -0.05 |
| Surprise Percentage | -45.9459% | -16.6667% | -5% | -37.5% | -15.141% | -5.8824% | 20% | 15.7895% | 5% | 20% | -52.6316% | -27.7778% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLPT
2026-04-15 00:39:42
The article discusses ClearPoint Neuro (CLPT) stock rising by 8.1%, questioning the sustainability of this strength. Investors are prompted to consider if the recent price movement indicates a lasting positive trend for the company's shares.
2026-04-13 15:58:00
This article analyzes Clearpoint Neuro, Inc. (NASDAQ: CLPT) using algorithmic entry frameworks, highlighting weak near and mid-term sentiment despite a neutral long-term outlook. It identifies an exceptional 159.0:1 risk-reward setup targeting a 52.4% gain and outlines three distinct AI-generated trading strategies for different risk profiles. The analysis includes a multi-timeframe signal breakdown with support and resistance levels.
2026-04-10 20:40:05
ClearPoint Neuro, Inc. (NASDAQ: CLPT) is seeking stockholder approval for a Seventh Amended and Restated 2013 Incentive Compensation Plan at its virtual annual meeting on May 20, 2026. The proposed plan would add 1,000,000 shares to the equity incentive pool, increasing the total reserve to 7,806,250 shares, representing approximately 3% of fully diluted shares, to help attract and retain talent. Stockholders will also vote on the election of seven directors, the ratification of Cherry Bekaert LLP as auditor, and an advisory say-on-pay for executive compensation; the board recommends "FOR" all proposals.
2026-04-02 19:09:12
ClearPoint Neuro director R. John Fletcher received a grant of 1,270 shares of common stock as payment for fees under the company’s Non-Employee Director Compensation Plan. The shares were issued at $9.10 each and were part of the Sixth Amended and Restated 2013 Incentive Compensation Plan. Following this transaction, Fletcher directly holds 117,932 shares of ClearPoint Neuro common stock.
2026-04-02 19:09:12
ClearPoint Neuro director Pascal E. R. Girin was granted 755 shares of Common Stock as compensation, valued at $9.10 per share. This award, made under the company's incentive and non-employee director compensation plans, increases his direct holdings to 98,206 shares. The transaction, reported in a Form 4 SEC filing, was a compensation grant rather than a market purchase, reflecting fees owed to the director.
2026-04-02 19:09:12
ClearPoint Neuro director Timothy T. Richards was granted 442 shares of common stock as a fee payment, valued at $9.10 per share. This award was part of the company's incentive compensation plan and director compensation plan, and it was settled at the closing price on March 31, 2026. Following this transaction, Richards directly holds 80,196 shares of ClearPoint Neuro common stock, indicating a routine compensation event rather than an open-market purchase.
